Orforglipron

• Chronic weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and more physical activity (Foundayo label)

Orforglipron is a once-daily GLP-1 pill sold as Foundayo. FDA approved it on April 1, 2026, for chronic weight management in adults with obesity or overweight with a weight-related health condition. It is the first GLP-1 medicine that is not a peptide: it is a small molecule, which is why it can be swallowed as an ordinary tablet and taken with or without food. It joins the Wegovy pill, a tablet form of semaglutide, as one of two oral GLP-1 options for weight loss.

How Orforglipron Works

Like injectable GLP-1 medicines, orforglipron activates the GLP-1 receptor, the target of a gut hormone released after meals. That lowers appetite, slows stomach emptying, improves insulin release when blood sugar is high and lowers glucagon. People feel full on smaller portions and have fewer food cravings.

What is new is its chemistry. Semaglutide and tirzepatide are peptides, chains of amino acids that the stomach would normally digest. Oral semaglutide gets around that with an absorption enhancer and strict rules: an empty stomach, a small sip of water and a 30-minute wait before eating. Orforglipron is a small molecule that survives digestion, so the Foundayo label allows it to be taken at any time of day, with or without food. Its half-life is 29 to 49 hours, so daily dosing keeps levels steady.

FDA Approval and What the Trials Showed

FDA approved orforglipron 50 days after Lilly filed, under the agency's Commissioner's National Priority Voucher pilot program. The approval rested on two 72-week trials. The first enrolled about 3,100 adults with obesity, or overweight with a related condition, who did not have diabetes. The second enrolled about 1,600 adults with overweight or obesity and type 2 diabetes. Details are listed at ClinicalTrials.gov.

In the first trial, average weight loss at the highest dose was roughly 11 percent of body weight, compared with about 2 percent on placebo. People with type 2 diabetes lost somewhat less, which is typical for every weight loss medicine. That is less than the average loss seen with injectable tirzepatide in its trials, so the pill trades some effectiveness for convenience. The trials were not head-to-head, and individual results vary widely.

What It Is Not Approved For

The current label covers weight management only. Although it was studied in people with type 2 diabetes, orforglipron does not yet carry a separate diabetes indication, and people with diabetes may still need their other glucose-lowering medicines adjusted while taking it.

Dosing and How to Take It

Everyone starts at 0.8 mg once daily. After at least 30 days the dose goes to 2.5 mg, then 5.5 mg. From there it can rise to 9 mg, 14.5 mg and a maximum of 17.2 mg, with at least 30 days at each step, depending on response and side effects. There is no single target dose; the right dose is the one that works and that you tolerate.

Swallow the tablet whole once a day. Do not crush, split or chew it, and never take two in one day. If you miss seven or more days in a row, call us before restarting, since you may need to begin again at a lower dose.

Side Effects

Stomach symptoms are the most common, as with all GLP-1 medicines. At the higher doses in the trials, about a third of people had nausea, and about a quarter had constipation, diarrhea or vomiting. They are usually worst after a dose increase. Smaller meals, avoiding greasy foods, stopping when full and staying hydrated help; our guide to getting the most out of GLP-1 medications covers the details.

The label also notes a small rise in heart rate and occasional low blood pressure, especially in people taking blood pressure medicines, so we check both at follow-up visits.

Boxed Warning and Serious Risks

Foundayo carries the same boxed warning as other GLP-1 medicines for thyroid C-cell tumors seen in rodents. It is not used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Other serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, severe allergic reactions and aspiration during anesthesia, so tell your surgeon or anesthesiologist that you take it.

Drug Interactions Matter More With This Pill

Because orforglipron is broken down by the liver enzyme CYP3A4, it has more drug interactions than injectable GLP-1 medicines. Some antibiotics and antifungals raise its levels, and seizure medicines and rifampin lower them. It roughly doubles simvastatin levels. Bring a complete medication list, including supplements such as St. John's wort, to your visit.

Who Is a Good Candidate for a GLP-1 Pill

Orforglipron may suit adults who meet the criteria for weight loss medication and who prefer a daily tablet to a weekly shot, including people who dislike needles, travel often, or find it hard to keep injectable pens refrigerated. Because it has no fasting rules, it is easier to fit around breakfast and morning medicines than oral semaglutide.

It may be a less good fit for people who need the largest possible weight loss, such as those with very high BMI or severe obstructive sleep apnea, where tirzepatide has stronger results. People who take medicines with major CYP3A4 interactions, or who have trouble remembering a daily pill, may do better with a weekly injection. Anyone with a history of pancreatitis, severe gastroparesis, or medullary thyroid cancer in the family needs a careful discussion first.

Getting Started in St. Petersburg

Our physician-led weight loss program offers both pills and injections, and we help you choose based on your health, your routine and your coverage. We check baseline labs at our in-office lab, adjust other medicines as weight comes down, and follow up during each dose step. To see whether orforglipron is a good fit, schedule a visit.